GoAI
Get started
Quest Diagnostics Incorporated logo

Quest Diagnostics Incorporated

DGX

NYSEHealthcareMedical - Diagnostics & Research

Open in GoAI

Previous close

$244.39

+$3.09 · +1.28%

Aug 21, 4:00 PM ET

DGX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

89

Deep Value

Momentum

46

Neutral

Sentiment

68

Bullish

Risk resilience

83

Low Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
James E. Davis
Listed since
Dec 17, 1996
Employees
51,500

Market position

Day range

Current $244.39

52-week range

Current $244.39

Open
$240.81
Previous close
$241.3
Volume
733.76K
0.77× average
Average volume
950.57K
Average daily volume
Market cap
26.97B USD
Beta
0.55
Market reference 1
50-day average
$219.31
+11.44% above average
200-day average
$198.18
+23.32% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
25.76B USD
EV / EBITDA
11.74×
Earnings yield
5.15%
Free cash flow yield
7.06%

Profitability & efficiency

Return on equity
13.84%
Return on assets
6.11%
Return on invested capital
8.43%

Financial health

Current ratio
1.04×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends42%30%18%6%Gross margin, FY2021: 39.02%Gross margin, FY2022: 34.74%Gross margin, FY2023: 33.17%Gross margin, FY2024: 32.86%Gross margin, FY2025: 31.93%Operating margin, FY2021: 22.07%Operating margin, FY2022: 14.45%Operating margin, FY2023: 13.64%Operating margin, FY2024: 13.63%Operating margin, FY2025: 14.53%Net margin, FY2021: 18.49%Net margin, FY2022: 9.57%Net margin, FY2023: 9.23%Net margin, FY2024: 8.82%Net margin, FY2025: 8.99%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 39.02%. Gross margin FY2022 34.74%. Gross margin FY2023 33.17%. Gross margin FY2024 32.86%. Gross margin FY2025 31.93%. Operating margin FY2021 22.07%. Operating margin FY2022 14.45%. Operating margin FY2023 13.64%. Operating margin FY2024 13.63%. Operating margin FY2025 14.53%. Net margin FY2021 18.49%. Net margin FY2022 9.57%. Net margin FY2023 9.23%. Net margin FY2024 8.82%. Net margin FY2025 8.99%.

Income trends

Revenue

11.04B USD+11.78%

Operating income

1.6B USD+19.09%

Net income

992M USD+13.89%
Income trends across reported periods12.05B USD7.98B USD3.91B USD−164.1M USDRevenue, FY2021: 10.79B USDRevenue, FY2022: 9.88B USDRevenue, FY2023: 9.25B USDRevenue, FY2024: 9.87B USDRevenue, FY2025: 11.04B USDOperating income, FY2021: 2.38B USDOperating income, FY2022: 1.43B USDOperating income, FY2023: 1.26B USDOperating income, FY2024: 1.35B USDOperating income, FY2025: 1.6B USDNet income, FY2021: 2B USDNet income, FY2022: 946M USDNet income, FY2023: 854M USDNet income, FY2024: 871M USDNet income, FY2025: 992M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 10.79B USD. Revenue FY2022 9.88B USD. Revenue FY2023 9.25B USD. Revenue FY2024 9.87B USD. Revenue FY2025 11.04B USD. Operating income FY2021 2.38B USD. Operating income FY2022 1.43B USD. Operating income FY2023 1.26B USD. Operating income FY2024 1.35B USD. Operating income FY2025 1.6B USD. Net income FY2021 2B USD. Net income FY2022 946M USD. Net income FY2023 854M USD. Net income FY2024 871M USD. Net income FY2025 992M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue11.04B USD9.87B USD9.25B USD9.88B USD10.79B USD
Cost of goods sold7.51B USD6.63B USD6.2B USD6.45B USD6.58B USD
Gross profit3.52B USD3.24B USD3.07B USD3.43B USD4.21B USD
Selling, general, and administrative1.97B USD1.77B USD1.62B USD1.87B USD1.73B USD
Operating expenses1.92B USD1.9B USD1.81B USD2.01B USD1.83B USD
Interest income13M USD25M USD11M USD10M USD1M USD
Interest expense277M USD226M USD163M USD148M USD152M USD
Depreciation and amortization570M USD493M USD439M USD437M USD408M USD
Operating income1.6B USD1.35B USD1.26B USD1.43B USD2.38B USD
Net income992M USD871M USD854M USD946M USD2B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+3.91%
11 comparable reports
Latest EPS result
3.12
Estimate 2.82 · Beat by 10.64%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates3.242.842.432.03Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 30, 2025: actual 2.23, estimate 2.19, surprise +1.83%, Beat. Q2 2025, reported Apr 22, 2025: actual 2.21, estimate 2.15, surprise +2.79%, Beat. Q3 2025, reported Jul 22, 2025: actual 2.62, estimate 2.57, surprise +1.95%, Beat. Q4 2025, reported Oct 21, 2025: actual 2.6, estimate 2.5, surprise +4.00%, Beat. Q1 2026, reported Feb 10, 2026: actual 2.42, estimate 2.36, surprise +2.54%, Beat. Q2 2026, reported Apr 21, 2026: actual 2.5, estimate 2.37, surprise +5.49%, Beat. Q3 2026, reported Jul 23, 2026: actual 3.12, estimate 2.82, surprise +10.64%, Beat. Q4 2026, reported Oct 20, 2026: actual —, estimate 2.85, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates3.16B2.93B2.69B2.46BQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 30, 2025: actual 2.62B USD, estimate 2.58B USD, surprise +1.65%, Beat. Q2 2025, reported Apr 22, 2025: actual 2.65B USD, estimate 2.63B USD, surprise +0.83%, Beat. Q3 2025, reported Jul 22, 2025: actual 2.76B USD, estimate 2.73B USD, surprise +1.32%, Beat. Q4 2025, reported Oct 21, 2025: actual 2.82B USD, estimate 2.74B USD, surprise +2.94%, Beat. Q1 2026, reported Feb 10, 2026: actual 2.81B USD, estimate 2.75B USD, surprise +1.88%, Beat. Q2 2026, reported Apr 21, 2026: actual 2.9B USD, estimate 2.83B USD, surprise +2.35%, Beat. Q3 2026, reported Jul 23, 2026: actual 3.04B USD, estimate 2.97B USD, surprise +2.36%, Beat. Q4 2026, reported Oct 20, 2026: actual —, estimate 3.04B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$244.5

0.05% upside
Past 12 months12-month forecastHigh $260Average $244.5Low $225

DGX peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

+0.83%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

+1.07%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

+1.21%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

+2.39%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

+1.37%

Novartis AG logo

NVS

Novartis AG

$158.86

+1.68%

ETFs holding DGX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
821.35M
Weight
0.04%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard S&P 500 ETF logoVanguard S&P 500 ETFVOO
Market value
677.02M
Weight
0.04%
AUM
1.7T USD
Expense ratio
0.03%
Price / 1D
$703.71+0.39%
Vanguard Morningstar Mid-Cap ETF logoVanguard Morningstar Mid-Cap ETFVO
Market value
558.22M
Weight
0.25%
AUM
224.7B USD
Expense ratio
0.03%
Price / 1D
$82.97+0.53%
iShares Core S&P 500 ETF logoiShares Core S&P 500 ETFIVV
Market value
359.21M
Weight
0.04%
AUM
891.84B USD
Expense ratio
0.03%
Price / 1D
$769.31+0.39%
State Street SPDR S&P 500 ETF logoState Street SPDR S&P 500 ETFSPY
Market value
332.16M
Weight
0.04%
AUM
817.87B USD
Expense ratio
0.09%
Price / 1D
$765.72+0.41%
Vanguard Morningstar Value ETF logoVanguard Morningstar Value ETFVTV
Market value
245.76M
Weight
0.10%
AUM
256.5B USD
Expense ratio
0.03%
Price / 1D
$226.4+0.54%
Invesco S&P 500 Equal Weight ETF logoInvesco S&P 500 Equal Weight ETFRSP
Market value
221.12M
Weight
0.22%
AUM
100.27B USD
Expense ratio
0.20%
Price / 1D
$221.67+0.63%
State Street Health Care Select Sector SPDR ETF logoState Street Health Care Select Sector SPDR ETFXLV
Market value
192.13M
Weight
0.43%
AUM
44.76B USD
Expense ratio
0.08%
Price / 1D
$174.62+1.29%

Continue in GoAI

Research DGX

research.disclaimer